Department of Pharmacology and Institute for Environmental Medicine, University of Pennsylvania School of Medicine, Medical Center, 36th Street & Hamilton Walk, Philadelphia, PA 19104, USA.
Drug Deliv. 1998;5(3):197-206. doi: 10.3109/10717549809052035.
Internalization of antibodies to thrombomodulin (TM) may provide a mechanism for intraendothelial targeting of drugs or genes. This study characterized three monoclonal antibodies against human TM (mAb 1009,1029, and 1045) and examined their internalization by human umbilical vein endothelial cells (HUVEC). It assessed binding of antibodies to recombinant human TM containing chondroitin sulfate (complete, cTM) and TM lacking chondroitin sulfate (incomplete, iTM). Direct RIA, indirect RIA, and ELISA and competitive ELISA show that (1) mAb 1009 binds to both cTM and iTM independently of divalent cations; (2) binding of mAb 1029 to iTM requires divalent cations, while binding to cTM is cation-independent; (3) mAb 1045 binds selectively to cTM independently of divalent cations. Binding of all three antibodies to the surface TM in HUVEC at 4 degrees C was similar by indirect immunostaining. In permeabilized HUVEC, however, mAb 1009 and 1029 provide brighter intracellular staining than mAb 1045. Uptake of (125)I-mAb 1009 by HUVEC at 37 degrees C was significantly higher than that of (125)I-mAb 1045. Low temperature markedly suppresses binding of (125)I-mAb 1009 to HUVEC, but has no effect on (125)I-mAb 1045 binding. About 80% of radiolabeled mAb 1045 bound to HUVEC at 37 degrees C could be eluted by acidic buffer from the cell surface, but only 40% of mAb 1009 and 1029 was elutable at these conditions. About 70-80 % of (125)I in cell lysates was TCA-soluble after HUVEC incubation with either mAb 1009 and 1029, but only 10 and 2.5% of (125)I was TCA-soluble in cell lysates and medium after 90 min incubation with (125)I-mAb 1045 at 37 degrees C. Therefore, HUVEC internalize and degrade an mAb that reacts with iTM, yet do not internalize an mAb that reacts selectively with cTM (mAb 1045). This result implies that either HUVEC do not internalize cTM constitutively or mAb 1045 suppresses TM internalization. Therefore, antibodies recognizing different TM epitopes might provide targeting of drugs to different cellular compartments.
抗体对血栓调节蛋白(TM)的内化可能为药物或基因的内皮内靶向提供一种机制。本研究对三种针对人 TM 的单克隆抗体(mAb 1009、1029 和 1045)进行了表征,并研究了它们在人脐静脉内皮细胞(HUVEC)中的内化情况。评估了抗体与含有硫酸软骨素的重组人 TM(完整,cTM)和缺乏硫酸软骨素的 TM(不完整,iTM)的结合。直接 RIA、间接 RIA、ELISA 和竞争 ELISA 表明:(1) mAb 1009 独立于二价阳离子与 cTM 和 iTM 结合;(2) mAb 1029 与 iTM 的结合需要二价阳离子,而与 cTM 的结合则不需要;(3) mAb 1045 选择性地与 cTM 结合,独立于二价阳离子。间接免疫染色显示,三种抗体在 4°C 时在 HUVEC 表面的 TM 结合相似。然而,在通透的 HUVEC 中,mAb 1009 和 1029 提供的细胞内染色比 mAb 1045 更亮。37°C 时 HUVEC 摄取 (125)I-mAb 1009 的速度明显高于 (125)I-mAb 1045。低温显著抑制 (125)I-mAb 1009 与 HUVEC 的结合,但对 (125)I-mAb 1045 的结合无影响。在 37°C 时,约 80%放射性标记的 mAb 1045 可被酸性缓冲液从细胞表面洗脱,但在这些条件下,mAb 1009 和 1029 仅可洗脱 40%。用 mAb 1009 和 1029 孵育 HUVEC 后,约 70-80%的 (125)I 在细胞裂解物中可被 TCA 溶解,但在用 (125)I-mAb 1045 在 37°C 孵育 90 分钟后,只有 10%和 2.5%的 (125)I 在细胞裂解物和培养基中可被 TCA 溶解。因此,HUVEC 内化并降解与 iTM 反应的抗体,但不内化与 cTM(mAb 1045)选择性反应的抗体。这一结果表明,HUVEC 要么不持续内化 cTM,要么 mAb 1045 抑制 TM 内化。因此,识别不同 TM 表位的抗体可能为药物靶向不同的细胞区室提供途径。